Literature DB >> 11549586

The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains.

M L Schmidt1, T Schuck, S Sheridan, M P Kung, H Kung, Z P Zhuang, C Bergeron, J S Lamarche, D Skovronsky, B I Giasson, V M Lee, J Q Trojanowski.   

Abstract

A novel Congo red-derived fluorescent probe (trans, trans),-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB) that binds to amyloid plaques of postmortem Alzheimer's disease brains and in transgenic mouse brains in vivo was designed as a prototype imaging agent for Alzheimer's disease. In the current study, we used BSB to probe postmortem tissues from patients with various neurodegenerative diseases with diagnostic lesions characterized by fibrillar intra- or extracellular lesions and compared these results with standard histochemical dyes such as thioflavin S and immunohistochemical stains specific for the same lesions. These data show that BSB binds not only to extracellular amyloid beta protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins and suggests that radioiodinated BSB derivatives or related ligands may be useful imaging agents to monitor diverse amyloids in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549586      PMCID: PMC1850468          DOI: 10.1016/s0002-9440(10)61769-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease.

Authors:  R Guntern; C Bouras; P R Hof; P G Vallet
Journal:  Experientia       Date:  1992-01-15

2.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

Authors:  T Iwatsubo; A Odaka; N Suzuki; H Mizusawa; N Nukina; Y Ihara
Journal:  Neuron       Date:  1994-07       Impact factor: 17.173

3.  Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease.

Authors:  M L Schmidt; V Zhukareva; K L Newell; V M Lee; J Q Trojanowski
Journal:  Acta Neuropathol       Date:  2001-05       Impact factor: 17.088

4.  Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.

Authors:  Z P Zhuang; M P Kung; C Hou; D M Skovronsky; T L Gur; K Plössl; J Q Trojanowski; V M Lee; H F Kung
Journal:  J Med Chem       Date:  2001-06-07       Impact factor: 7.446

5.  Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement.

Authors:  P Vermersch; Y Robitaille; L Bernier; A Wattez; D Gauvreau; A Delacourte
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

6.  Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration.

Authors:  H Ksiezak-Reding; K Morgan; L A Mattiace; P Davies; W K Liu; S H Yen; K Weidenheim; D W Dickson
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

7.  Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease.

Authors:  W E Klunk; M L Debnath; J W Pettegrew
Journal:  Neurobiol Aging       Date:  1994 Nov-Dec       Impact factor: 4.673

8.  Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe.

Authors:  W E Klunk; M L Debnath; J W Pettegrew
Journal:  Neurobiol Aging       Date:  1995 Jul-Aug       Impact factor: 4.673

9.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

Authors:  D W Dickson; H A Crystal; L A Mattiace; D M Masur; A D Blau; P Davies; S H Yen; M K Aronson
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

10.  Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Authors:  S Flament; A Delacourte; M Verny; J J Hauw; F Javoy-Agid
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more
  20 in total

1.  Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Authors:  David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2017-08-19       Impact factor: 10.422

2.  Rational design of amyloid binding agents based on the molecular rotor motif.

Authors:  Jeyanthy Sutharsan; Marianna Dakanali; Christina C Capule; Mark A Haidekker; Jerry Yang; Emmanuel A Theodorakis
Journal:  ChemMedChem       Date:  2010-01       Impact factor: 3.466

Review 3.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

4.  A KLVFFAE-Derived Peptide Probe for Detection of Alpha-Synuclein Fibrils.

Authors:  Amy Wood; Edward Chau; Yanxi Yang; Jin Ryoun Kim
Journal:  Appl Biochem Biotechnol       Date:  2019-11-27       Impact factor: 2.926

Review 5.  Spreading of pathology in neurodegenerative diseases: a focus on human studies.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2015-01-15       Impact factor: 34.870

Review 6.  Harnessing the immune system for treatment and detection of tau pathology.

Authors:  Erin E Congdon; Senthilkumar Krishnaswamy; Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 7.  Emerging Diagnostic and Therapeutic Strategies for Tauopathies.

Authors:  David Coughlin; David J Irwin
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 8.  Tauopathies as clinicopathological entities.

Authors:  David J Irwin
Journal:  Parkinsonism Relat Disord       Date:  2015-09-08       Impact factor: 4.891

9.  Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status.

Authors:  Minna Groenning
Journal:  J Chem Biol       Date:  2009-08-20

10.  Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene].

Authors:  Ana Velasco; Graham Fraser; Patrice Delobel; Bernardino Ghetti; Isabelle Lavenir; Michel Goedert
Journal:  FEBS Lett       Date:  2008-02-20       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.